Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis

Figures & data

Figure 1. Residual disease at week 12. Mean values for (A) BSA, (B) PASI total score, (C) DLQI total score, and (D) Psoriasis Symptom Inventory total score for subjects with sPGA score of ≥2 (black bars), 1 (gray bars), or 0 (white bars) at week 12 of treatment are shown. Error bars represent standard deviations. *p < 0.05; †p ≤ 0.001; ‡p ≤ 0.0001 for comparison with sPGA of 0. BSA, body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; SD, standard deviation; sPGA, static physician global assessment.

Table 1. Demographics and clinical characteristics at baseline.

	sPGA score at week 12
	≥2 N = 83	1 N = 48	0 N = 57
Sex, n female (%)	31 (37)	16 (33)	20 (35)
Age, mean years (SD)	43 (12)	42 (12)	43 (13)
Race, n white (%)	72 (87)	42 (88)	53 (93)
History of psoriatic arthritis^a, n (%)	18 (22)	10 (21)	15 (26)
Affected BSA, mean % (SD)	25 (15)	25 (15)	22 (12)
PASI, mean score (SD)	20.0 (6.7)	19.0 (8.5)	18.3 (5.0)
Psoriasis Symptom Inventory, mean score (SD)	19.6 (6.3)^b	17.4 (7.2)	17.2 (7.4)^c
DLQI, mean score (SD)	12.6 (6.9)	11.7 (7.2)^d	10.6 (6.1)

BSA, body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; SD, standard deviation; sPGA, static physician global assessment.

^aHistory of psoriatic arthritis was self-reported.

^bSeventy-eight subjects had a baseline Psoriasis Symptom Inventory assessment.

^cFifty-four subjects had a baseline Psoriasis Symptom Inventory assessment.

^dForty-seven subjects had a baseline DLQI assessment.

Table 2. Clinical response and patient-reported outcome improvements from baseline to week 12.

	PASI score at week 12				sPGA score at week 12
	<50	50 to <75	75 to <100	100	≥2	1	0
DLQI score = 0
n/N1 (%)	0/57 (0)	1/26 (3.8)	25/47 (53.2)	34/56 (60.7)	4/83 (4.8)	21/46 (45.7)	35/57 (61.4)
95% CI of %	0.0–6.3	0.1–19.6	38.1–67.9	46.8–73.5	1.3–11.9	30.9–61.0	47.6–74.0
p Value^a	<0.001	<0.001	0.492		<0.001	0.148
Psoriasis Symptom  Inventory score = 0
n/N1 (%)	0/54 (0)	0/26 (0)	21/46 (45.7)	35/54 (64.8)	5/79 (6.3)	15/46 (32.6)	36/55 (65.5)
95% CI of %	0.0–6.6	0.0–13.2	30.9–61.0	50.6–77.3	2.1–14.2	19.5–48.0	51.4–77.8
p Value^b	<0.001	<0.001	0.038		<0.001	0.001

BMI, body mass index; CI, confidence interval; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; N1, number of subjects with assessment; sPGA, static physician global assessment.

^ap Value is for comparison between each PASI response group and the PASI 100 group or between each sPGA response group and the sPGA of 0 group and is based on the Cochran–Mantel–Haenszel test stratified by baseline BMI group (≤35 kg/m², >35 kg/m²) and baseline DLQI score (≤median, >median).

^bp Value is for comparison between each PASI response group and the PASI 100 group or between each sPGA response group and the sPGA of 0 group and is based on the Cochran–Mantel–Haenszel test stratified by baseline BMI group (≤35 kg/m², >35 kg/m²) and baseline Psoriasis Symptom Inventory score (≤median, >median).

Figure 2. Residual psoriasis symptoms. The percentage of subjects with sPGA score of ≥2 (black bars), 1 (gray bars), or 0 (white bars) at week 12 of treatment who achieved (A) a DLQI subscale score of 0, (B) DLQI item score, or (C) a Psoriasis Symptom Inventory item score of 0 at week 12 are shown. Error bars represent 95% confidence intervals (CIs). *p < 0.05; †p < 0.01; ‡p < 0.001 for comparison with sPGA of 0. DLQI, Dermatology Life Quality Index; sPGA, static physician global assessment.